Literature DB >> 12620646

Regulation of chemokine receptor expression in human microglia and astrocytes.

Geraldine Flynn1, Seema Maru, Jane Loughlin, Ignacio A Romero, David Male.   

Abstract

It has been proposed that the positioning of mobile cells within a tissue is determined by their overall profile of chemokine receptors. This study examines the profiles of chemokine receptors expressed on resting and activated adult human microglial cells, astrocytes and a microglial cell line, CHME3. Microglia express highest levels of CXCR1, CXCR3 and CCR3. Astrocytes also have moderate levels of CXCR1 and CXCR3, and some CCR3, while both cell types also expressed CCR4, CCR5, CCR6, CXCR2, CXCR4 and CXCR5 at lower levels. Activation of the cells with the inflammatory cytokine tumour necrosis factor-alpha (TNFalpha) and interferon-gamma (IFNgamma) increased the expression of some but not all receptors over a period of 24 h. Microglia showed moderate enhancement of receptor expression, while astrocytes responded particularly strongly to TNFalpha with enhanced CXCR3, CCR3 and CXCR1. However, the migratory and proliferative responses of the microglia and astrocytes to the same chemokine were different, with microglia migrating and astrocytes proliferating in response to CXCL10. The data indicates a mechanism by which activated microglia and astrocytes become selectively more sensitive to inflammatory chemokines during CNS disease, and the paper discusses which of the many chemokines present in CNS would have priority of action on microglia and astrocytes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12620646     DOI: 10.1016/s0165-5728(03)00009-2

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  84 in total

Review 1.  Chemokines and glial cells: a complex network in the central nervous system.

Authors:  Elena Ambrosini; Francesca Aloisi
Journal:  Neurochem Res       Date:  2004-05       Impact factor: 3.996

Review 2.  Role of microglia in central nervous system infections.

Authors:  R Bryan Rock; Genya Gekker; Shuxian Hu; Wen S Sheng; Maxim Cheeran; James R Lokensgard; Phillip K Peterson
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

3.  Cytokine production by a human microglial cell line: effects of beta-amyloid and alpha-melanocyte-stimulating hormone.

Authors:  Catharina Lindberg; Erik Hjorth; Claes Post; Bengt Winblad; Marianne Schultzberg
Journal:  Neurotox Res       Date:  2005-11       Impact factor: 3.911

Review 4.  Microglia biology in health and disease.

Authors:  Gwenn A Garden; Thomas Möller
Journal:  J Neuroimmune Pharmacol       Date:  2006-03-25       Impact factor: 4.147

Review 5.  Neuronal chemokines: versatile messengers in central nervous system cell interaction.

Authors:  A H de Haas; H R J van Weering; E K de Jong; H W G M Boddeke; K P H Biber
Journal:  Mol Neurobiol       Date:  2007-07-10       Impact factor: 5.590

6.  Neuroprotection and remyelination after autoimmune demyelination in mice that inducibly overexpress CXCL1.

Authors:  Kakuri M Omari; Sarah E Lutz; Laura Santambrogio; Sergio A Lira; Cedric S Raine
Journal:  Am J Pathol       Date:  2008-12-18       Impact factor: 4.307

7.  Aging sensitizes mice to behavioral deficits induced by central HIV-1 gp120.

Authors:  J Abraham; S Jang; J P Godbout; J Chen; K W Kelley; R Dantzer; R W Johnson
Journal:  Neurobiol Aging       Date:  2006-12-15       Impact factor: 4.673

8.  The opioid antagonist, β-funaltrexamine, inhibits NF-κB signaling and chemokine expression in human astrocytes and in mice.

Authors:  Randall L Davis; Subhas Das; J Thomas Curtis; Craig W Stevens
Journal:  Eur J Pharmacol       Date:  2015-05-22       Impact factor: 4.432

9.  The opioid antagonist, beta-funaltrexamine, inhibits chemokine expression in human astroglial cells.

Authors:  Randall L Davis; Daniel J Buck; Neda Saffarian; Craig W Stevens
Journal:  J Neuroimmunol       Date:  2007-05-01       Impact factor: 3.478

10.  Therapeutic targets and limits of minocycline neuroprotection in experimental ischemic stroke.

Authors:  Noriyuki Matsukawa; Takao Yasuhara; Koichi Hara; Lin Xu; Mina Maki; Guolong Yu; Yuji Kaneko; Kosei Ojika; David C Hess; Cesar V Borlongan
Journal:  BMC Neurosci       Date:  2009-10-06       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.